Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages
- PMID: 17654345
- DOI: 10.1080/00365540701225744
Alpha-1-antitrypsin (AAT) anomalies are associated with lung disease due to rapidly growing mycobacteria and AAT inhibits Mycobacterium abscessus infection of macrophages
Abstract
Rapidly growing mycobacteria (RGM) are ubiquitous in the environment but cause lung disease in only a fraction of exposed individuals. This variable susceptibility to disease implies vulnerability to RGM infection due to weakness in host defense. Since most persons who contract RGM lung disease have no known host defense defect, it is likely that uncharacterized host deficiencies exist that predispose to RGM infection. Alpha-1-antitrypsin (AAT) is a host factor that may protect individuals from respiratory infections. Therefore, we assessed AAT protein anomalies as a risk factor for RGM lung disease. In a cohort of 100 patients with RGM lung disease, Mycobacterium (M.) abscessus was the most prevalent organism, isolated in 64 (64%) subjects. Anomalous AAT proteins were present in 27% of the cohort, which is 1.6 times the estimated prevalence of anomalous AAT proteins in the United States population (p=0.008). In in vitro studies, both AAT and a synthetic inhibitor of serine proteases suppressed M. abscessus infection of monocyte-derived macrophages by up to 65% (p<0.01). AAT may be an anti-RGM host-defense factor, and anomalous AAT phenotypes or AAT deficiency may constitute risk factors for pulmonary disease due to RGM.
Similar articles
-
Phenotypes and serum level of alpha-1-antitrypsin in lung cancer.J BUON. 2011 Oct-Dec;16(4):672-6. J BUON. 2011. PMID: 22331720
-
Host immune response to rapidly growing mycobacteria, an emerging cause of chronic lung disease.Am J Respir Cell Mol Biol. 2010 Oct;43(4):387-93. doi: 10.1165/rcmb.2009-0276TR. Epub 2010 Jan 15. Am J Respir Cell Mol Biol. 2010. PMID: 20081053 Review.
-
Heritability of lung function in severe alpha-1 antitrypsin deficiency.Hum Hered. 2009;67(1):38-45. doi: 10.1159/000164397. Epub 2008 Oct 17. Hum Hered. 2009. PMID: 18931508
-
Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting.Bull World Health Organ. 1997;75(5):397-415. Bull World Health Organ. 1997. PMID: 9447774 Free PMC article. Review.
-
Alpha-1 antitrypsin Null mutations and severity of emphysema.Respir Med. 2008 Jun;102(6):876-84. doi: 10.1016/j.rmed.2008.01.009. Epub 2008 Mar 18. Respir Med. 2008. PMID: 18353624
Cited by
-
Expanding the clinical indications for α(1)-antitrypsin therapy.Mol Med. 2012 Sep 7;18(1):957-70. doi: 10.2119/molmed.2011.00196. Mol Med. 2012. PMID: 22634722 Free PMC article. Review.
-
Revisiting John Snow to Meet the Challenge of Nontuberculous Mycobacterial Lung Disease.Int J Environ Res Public Health. 2019 Nov 1;16(21):4250. doi: 10.3390/ijerph16214250. Int J Environ Res Public Health. 2019. PMID: 31683836 Free PMC article. Review.
-
α1-Antitrypsin Binds to the Glucocorticoid Receptor with Anti-Inflammatory and Antimycobacterial Significance in Macrophages.J Immunol. 2022 Nov 1;209(9):1746-1759. doi: 10.4049/jimmunol.2200227. Epub 2022 Sep 26. J Immunol. 2022. PMID: 36162872 Free PMC article.
-
Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential.Front Immunol. 2024 Aug 19;15:1443297. doi: 10.3389/fimmu.2024.1443297. eCollection 2024. Front Immunol. 2024. PMID: 39224588 Free PMC article. Review.
-
Identification of nontuberculous mycobacteria isolated from household showerheads of patients with nontuberculous mycobacteria.Sci Rep. 2022 May 23;12(1):8648. doi: 10.1038/s41598-022-12703-6. Sci Rep. 2022. PMID: 35606401 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous